Table 1. Results for measurement of serum ProGRP and NSE in the diagnosis of SCLC.
| Stage | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | Positive LR | Negative LR |
|---|---|---|---|---|---|---|
| Total | ||||||
| ProGRP ≥66 ng/L | 86.5 | 96.5 | 74.0 | 98.2 | 24.4 | 0.1 |
| NSE ≥18 µg/L | 78.8 | 86.3 | 39.0 | 96.9 | 5.8 | 0.3 |
| I–II | ||||||
| ProGRP ≥56 ng/L | 93.6 | 92.2 | 20.3 | 99.8 | 12.0 | 0.1 |
| NSE ≥100 µg/L | 0 | 100.0 | 0 | 97.9 | – | 1 |
| ProGRP ≥66 ng/L | 85.5 | 97.2 | 39.0 | 99.7 | 30.0 | 0.2 |
| ProGRP ≥300 ng/L | 41.9 | 99.8 | 83.9 | 98.8 | 241.0 | 0.6 |
| III | ||||||
| ProGRP ≥71 ng/L | 85.5 | 96.6 | 84.1 | 96.9 | 25.1 | 0.2 |
| NSE ≥100 µg/L | 10.0 | 99.9 | 97.0 | 83.8 | 144.0 | 0.9 |
| ProGRP ≥66 ng/L | 85.8 | 95.8 | 81.6 | 96.9 | 20.6 | 0.2 |
| ProGRP ≥300 ng/L | 65.2 | 99.1 | 94.0 | 93.0 | 72.2 | 0.4 |
| IV | ||||||
| ProGRP ≥99 ng/L | 85.3 | 98.3 | 89.4 | 97.5 | 49.9 | 0.2 |
| NSE ≥100 µg/L | 29.8 | 99.3 | 87.6 | 89.4 | 41.6 | 0.7 |
| ProGRP ≥66 ng/L | 87.6 | 94.8 | 73.8 | 97.8 | 16.9 | 0.1 |
| ProGRP ≥300 ng/L | 74.8 | 99.2 | 93.9 | 95.9 | 90.5 | 0.3 |
ProGRP, roles of gastrin-releasing peptide; NSE, neuron-specific enolase; SCLC, small-cell lung cancer; PPV, positive predictive value; NPV, negative predictive value; LR, likelihood ratio.